ArticleHealth economics2019
A cost-effectiveness threshold based on the marginal returns of cardiovascular hospital spending.
Article in Health economics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 56 citations in OpenAlex.
- Cost-effectiveness analysis of bacterial vaginosis screening strategies in women attempting for natural conception.Cost effectiveness and resource allocation : C/E · 2026Article
- The value of health and well-being from a societal perspective: A willingness to pay experiment in the Netherlands.The European journal of health economics : HEPAC : health economics in prevention and care · 2026Article
- What Value Do Dutch Citizens Place on Health Interventions That Provide Greater Health Gains to Lower-Income Groups? A Discrete Choice Experiment.International journal of health policy and management · 2026Article
- Monetary value of health-a practical decision-making framework combining equity considerations and WTP.The European journal of health economics : HEPAC : health economics in prevention and care · 2025Article
- The impact of different perspectives on the cost-effectiveness of remote patient monitoring for patients with heart failure in different European countries.The European journal of health economics : HEPAC : health economics in prevention and care · 2025Article
- Estimating the Incremental Cost Per QALY Produced by the Spanish NHS: A Fixed-Effect Econometric Approach.PharmacoEconomics · 2025Article
- Use of Cost-Effectiveness Thresholds in Healthcare Public Policy: Progress and Challenges.Applied health economics and health policy · 2024Review
- A QALY is [still] a QALY is [still] a QALY? : Evaluating proportional shortfall as the answer to the problem of equity in healthcare allocations.BMC medical ethics · 2024Article
- Estimating the cost-effectiveness threshold of advanced non-small cell lung cancer in China using mean opportunity cost and contingent valuation method.Cost effectiveness and resource allocation : C/E · 2023Article
- 10 Years of AMNOG: What is the Willingness-to-Pay for Pharmaceuticals in Germany?Applied health economics and health policy · 2023Article
- The Value of Health in a Cost-Effectiveness Analysis: Theory Versus Practice.PharmacoEconomics · 2023Article
- The Broader Opportunity Costs in the Broader Cost-Effectiveness Analysis Framework.Applied health economics and health policy · 2023Article
- Estimating health system opportunity costs: the role of non-linearities and inefficiency.Cost effectiveness and resource allocation : C/E · 2022Article
- Supply-Side Cost-Effectiveness Thresholds: Questions for Evidence-Based Policy.Applied health economics and health policy · 2022Review
- How Responsive is Mortality to Locally Administered Healthcare Expenditure? Estimates for England for 2014/15.Applied health economics and health policy · 2022Article
- The Relevance of Including Future Healthcare Costs in Cost-Effectiveness Threshold Calculations for the UK NHS.PharmacoEconomics · 2022Article
- Accounting for country- and time-specific values in the economic evaluation of health-related projects relevant to low- and middle-income countries.Health policy and planning · 2022Article
- Avoiding Opportunity Cost Neglect in Cost-Effectiveness Analysis for Health Technology Assessment.Applied health economics and health policy · 2022Article
- Value-based drug pricing in the Biden era: Opportunities and prospects.Health services research · 2021Article
- How Effective is Marginal Healthcare Expenditure? New Evidence from England for 2003/04 to 2012/13.Applied health economics and health policy · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
Traditionally, threshold levels of cost-effectiveness have been derived from willingness-to-pay studies, indicating the consumption value of health (v-thresholds). However, it has been argued that v-thresholds need to be supplemented by so-called k-thresholds, which are based on the marginal returns to health care. The objective of this research is to estimate a k-threshold based on the marginal returns to cardiovascular disease (CVD) hospital care in the Netherlands. To estimate a k-threshold for hospital care on CVD, we proceed in two steps: First, we estimate the impact of hospital spending on mortality using a Bayesian regression modelling framework, using data on CVD mortality and CVD hospital spending by age and gender for the period 1994-2010. Second, we use life tables in combination with quality of life data to convert these estimates into a k-threshold expressed in euros per quality-adjusted life year gained. Our base case estimate resulted in an estimate of 41,000 per quality-adjusted life year gained. In our sensitivity analyses, we illustrated how the incorporation of prior evidence into the estimation pushes estimates downwards. We conclude that our base case estimate of the k-threshold may serve as a benchmark value for decision making in the Netherlands as well as for future research regarding k-thresholds.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.